Sinocompound announces commercial-scale production of QPhos ligand

The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution  for cross-coupling chemistry

11 Mar 2022
Ellie Abbott
Biochemist

Industry news

Sinocompound Catalysts Co., Ltd, a global provider of advanced homogeneous catalysts and ligands, has announced production of the phosphine-based QPhos ligand in kilogram quantities for commercial use. With this ligand now accessible on a large scale, scientists across the globe can incorporate QPhos-based catalysts in their drug discovery, screening and process development programs to optimize and streamline their product development phase.

Pharmaceutical companies invest significantly in drug development to optimize product synthesis and expedite their innovations to market. QPhos is a promising ligand in metal-catalyzed cross-coupling reactions, which are fundamental to construct carbon-based bonds featured in most drug scaffolds. However, until now QPhos has not been readily available in commercial quantities, hindering its adoption in process development and scale-up programs.

“There’s an enormous amount of untapped potential in ligands that scientists simply can’t access on a large scale, so they discount them from their screening programs,” says Dr Carin Seechurn, Associate Director – Technology Solutions, Sinocompound. “Our capability to scale-up the QPhos ligand represents a significant milestone in improving ligand accessibility for researchers. As we continue to expand our manufacturing processes thanks to our new plant in Tongling, we’re excited to provide more overlooked ligands and products commercially.”

QPhos is a robust dialkylarylphosphine ligand developed by Professor John Hartwig for metal-catalyzed cross-coupling reactions¹. Bulky and electron-rich, it performs excellently in many transformations including α-arylation of carbonyl compounds and late-stage C-C bond formation.

References

1. N. Kataoka, Q. Shelby, J. P. Stambuli, J. F. Hartwig, J. Org. Chem. 2002, 67, 16, 5553–5566

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags

High-Throughput ScreeningHigh-throughput screening (HTS) is an automated drug discovery technique for identification of active compounds against a compound library. Use HTS readers and integrated assay preparation / analysis workstations to screen your compounds. Identify active compounds against various HTS libraries, including membranes, proteins and peptides and HTS cell lines. Find the best high-throughput screening products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.High-Content ScreeningHigh-content screening (HCS), also known as high-content analysis (HCA), is a high-throughput technique used in drug discovery to identify substances that alter the phenotype of cells. HCS uses fluorescent microscopic imaging and automated image analysis to investigate cellular events such as apoptosis, cell viability, GPCR activation, oxide production, neurite outgrowth, and cell signaling. Find the best fluorescent labeling reagents, cellular assays, and high-content imaging systems in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.ScreeningUsing robotics, data processing and control software, liquid handling devices and sensitive detectors, screening allows a researcher to quickly conduct millions of chemical, genetic or pharmacological tests.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.Drug Discovery & Development Screening